---
Investor Relations

Price: ... AWKN (NEO)

About Awakn

Awakn Life Sciences is a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder.

OBJECTIVE:
To provide effective therapeutics to addiction sufferers in desperate need

STRATEGY:
To commercialize our R&D pipeline across multiple channels

Awakn corporate information

Download latest Awakn Corporate Presentation and visit Awakn Financials Info on Sedar.

acp

Conference Presentations

Analyst Coverage

FIRM

Stifel

Maxim Group LLC

H.C. Wainwright & Co.

ANALYST

Andrew Partheniou

Jason McCarthy

Patrick R. Trucchio

Press releases

Awakn Life Sciences Signs Drug Development Agreement With Catalent For Zydis® Technology (An Orally Disintegrating Tablet) To Conduct Feasibility Studies To Improve Differentiation Of Its MDMA Program

Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis® Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of its MDMA Program

TORONTO, CANADA, Sept, 12 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

Enquiries

Investor relations:

Anthony Tennyson
CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com

Media enquiries:

AMERICA AND CANADA:
KCSA Strategic Communications 
Anne Donohoe
adonohoe@KCSA.com

REST OF WORLD:
Gordo Whittaker,
CMO, Awakn Life Sciences

gordo@awaknlifesciences.com

Sign Up for Newsletter

Awakn_logo_corp

MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom

UK OFFICE
1 Regent Street, Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy

Back to top Arrow